



FIND IT[®] Cancer Hotspot Panel (NGS)

Information for patients

Purpose

Every cancer is different. We now know that there are combinations of genetic mutations that lead to certain types of cancer. These are known as the cancer's 'molecular signature' because they are specific to the individual cancer.

We now have tests to identify some of these cancer-causing genetic mutations.

The FIND IT test report contains detailed information about:

- The genetic changes in your cancer, i.e. the cancer signature
- Medications that are currently available which may assist in your treatment
- Clinical trials that may be relevant for your type of cancer

Genomic testing for cancer

A genetic test provides information that gives your doctor a better understanding of your cancer. This helps in making decisions about potential treatments.

Sonic Genetics uses the FIND IT test developed by a Canadian biotechnology company, Contextual Genomics. FIND IT examines the cancer signature by checking for more than 140 different mutations in no less than 30 genes at the same time. The test is being regularly upgraded to include more mutations and genes.

Most of the mutations included in FIND IT are targeted by drugs that are available now. The other mutations are targeted by drugs that are being evaluated in clinical trials. Your doctor can advise if you will be eligible for such a trial. A few of the mutations in FIND IT are for new treatments that will be tested in clinical trials in the near future.

Limitations

The FIND IT test is designed to detect some of the most common mutations that are currently known in cancer. If no mutations are found, it may be advisable to have further testing done to look for mutations elsewhere in the DNA of the cancer cells. Some types of genomic testing may not work if the DNA is of low quality – for example, DNA quality is lower in samples stored for more than two years before testing. Sometimes another biopsy is requested if you have been on other therapy since the last biopsy was done.

Testing procedure

Our laboratory scientists extract genetic material (DNA) from a small sample of the cancer that has been obtained at the time of biopsy or surgery. Our genetic pathologists and scientists compare the mutations detected by FIND IT with a detailed database of genetic changes and drug treatments in Australia and overseas.

Financial consent

By consenting overleaf, I confirm I have been informed about the purpose, scope and performance of the FIND IT test by my doctor. I understand that this test is performed from histopathology samples collected previously, that the sample will be requested from the holding laboratory, and that the result should be reviewed by my doctor in light of other findings. I consent to the FIND IT test being performed in whole or part as requested by my doctor and am aware that the laboratory will contact me for prepayment by credit card over the phone if criteria for Medicare or other reimbursement are not met.

I also understand that if my original tissue sample is held by a histopathology laboratory that is not part of the Sonic Healthcare network, a sample retrieval and processing fee may be applied by that laboratory and invoiced to me directly.

Medicare criteria (as of July 2019)

Indication	Item #	MBS rebate requirements
NSCLC	73337	A test of tumour tissue from a patient diagnosed with non-small cell lung cancer, shown to have non-squamous histology or histology not otherwise specified, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to epidermal growth factor receptor (EGFR) gene status for access to erlotinib, gefitinib or afatinib under the Pharmaceutical Benefits Scheme (PBS) are fulfilled.
NSCLC Relapse	73351	A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non-small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme (PBS) are fulfilled.
Melanoma	73336	A test of tumour tissue from a patient with unresectable stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib or vemurafenib under the Pharmaceutical Benefits Scheme (PBS) are fulfilled.
Colorectal	73338	A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if the requirements relating to rat sarcoma oncogene (RAS) gene mutation status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme (PBS) are fulfilled, if: (a) the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3 and 4; or (b) a RAS mutation is found.

Sonic Genetics

We are part of Sonic Healthcare which is Australia's largest pathology provider and the third largest pathology provider in the world. We employ highly qualified genetic pathologists, genetic scientists and molecular biologists and operate out of fully accredited laboratories throughout Australia, using state-of-the-art equipment. The test is performed in a NATA-accredited laboratory in Australia by Sullivan Nicolaides Pty Ltd (ABN 38 078 202 196, a subsidiary of Sonic Healthcare Limited).